Last week, President Trump spoke about his plans to lower prescription drug prices by increasing competition and creating incentives for them to lower prices.
His plan includes budget proposals to reform the Medicare Part D program, curbing abuse of FDA safety rules and continuing generic drug approvals,
The registration and reporting requirements of Clinicaltrials.gov are vital to informing the evidence base – but only if study sponsors actually use it and keep entries updated. A recent research letter in JAMA Internal Medicine suggests this is not happening often enough. That’s helpful for journalists to know if they are attempting to find all the recent evidence on a particular drug or intervention.
“Missing or incomplete reporting of clinical trial results and its scientific and ethical consequences are well documented,” wrote Kevin M. Fain, J.D., M.P.H., Dr.PH, and his team at the National Institutes of Health.
Photo: Ryan Basen Baltimore Health Commissioner Leana Wen, right, helps demonstrate how naloxone is administered.
Health journalists in Washington, D.C., participated in an all-day training session about reporting on the opioid crisis, hearing from treatment experts, medical providers and public health advocates.
The event took place Feb. 23 at the University of Maryland’s Philip Merrill College of Journalism, and was a partnership between the D.C. chapter of the Association of Health Care Journalists and the National Press Foundation. Continue reading
For Heather Wolford, a reporter for the Cumberland Times-News, covering the growing opioid crisis in the rural hills of Western Maryland was, quite literally, a calling.
Now two years into her health coverage of the epidemic, Wolford was driven by a journalist’s instinct to find out what was happening in her community, from those using the drugs, police officers and government officials, to family members on all sides of the crisis.
“When I repeatedly heard daily overdose calls over the office scanner, I asked my boss if I could dive into the crisis,” she said. Continue reading
Last week’s AHCJ webinar about responsible, accurate reporting on addiction and recovery issues pointed out the importance of sensitive, accurate coverage of the issue and ways in which journalists can improve their coverage.
AHCJ members who missed the live webcast can still watch the Aug. 24 presentation by speaker Tom Hill, M.S.W., vice president of addiction and recovery at the National Council for Behavioral Health. Continue reading
The death of musician Glen Campbell on Aug. 8 after a very public struggle with Alzheimer’s disease has again focused attention on whether science will ever find a drug that truly halts this devastating condition.
Deaths from Alzheimer’s are increasing, according to the nonprofit advocacy group UsAgainstAlzheimer’s. The organization, which has the goal of stopping Alzheimer’s by 2020, lobbies legislators to increase research funding. Some 35 drugs are in various phases of clinical trials. But as this excellent Pacific Standard article reports, the goal of a cure by 2020, or 2025, is iffy at best. Continue reading